Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A HULL

Allopathic & Osteopathic Physicians Dermatology

NPI
1124081849
CMS profile
142103
Location
ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$880.69

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $561.65 16
Amgen Inc. $97.92 4
Regeneron Healthcare Solutions, Inc. $61.05 3
E.R. Squibb & Sons, L.L.C. $47.18 2
GENZYME CORPORATION $45.95 2
Sandoz Inc. $38.29 2
Novartis Pharmaceuticals Corporation $15.51 1
Lilly USA, LLC $13.14 2

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A HULL

NPI 1124081849 · CMS profile ID 142103

Allopathic & Osteopathic Physicians / Dermatology

ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124081849?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $880.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $23.6412/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117282713 CMS
ABBVIE INC. $75.0012/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103155500 CMS
E.R. Squibb & Sons, L.L.C. $13.7810/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101727919 CMS
GENZYME CORPORATION $22.8210/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139724144 CMS
ABBVIE INC. $12.7710/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953402 CMS
Regeneron Healthcare Solutions, Inc. $17.0410/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114073127 CMS
ABBVIE INC. $19.1809/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953400 CMS
ABBVIE INC. $17.4909/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953398 CMS
E.R. Squibb & Sons, L.L.C. $33.4009/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101727896 CMS
ABBVIE INC. $24.0609/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953394 CMS
ABBVIE INC. $3.8409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953396 CMS
ABBVIE INC. $18.2708/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953392 CMS
ABBVIE INC. $19.1308/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953390 CMS
Novartis Pharmaceuticals Corporation $15.5108/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086782815 CMS
ABBVIE INC. $3.2008/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103155498 CMS
ABBVIE INC. $27.0007/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103155496 CMS
ABBVIE INC. $33.2506/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103155494 CMS
Lilly USA, LLC $12.9005/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136097060 CMS
Lilly USA, LLC $0.2405/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136097062 CMS
Sandoz Inc. $19.1005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089371190 CMS
Amgen Inc. $22.8804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117282711 CMS
Regeneron Healthcare Solutions, Inc. $20.5504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114073125 CMS
ABBVIE INC. $3.3704/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953388 CMS
Regeneron Healthcare Solutions, Inc. $23.4604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114073123 CMS
Amgen Inc. $25.1403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117282709 CMS
ABBVIE INC. $4.4603/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953386 CMS
ABBVIE INC. $15.8303/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103953384 CMS
GENZYME CORPORATION $23.1303/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139724022 CMS
ABBVIE INC. $107.5003/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103155492 CMS
Amgen Inc. $26.2602/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117282707 CMS
Sandoz Inc. $19.1902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089371158 CMS
ABBVIE INC. $177.3001/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103155490 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,430.05 27
PY2020 $231.11 11
PY2021 $627.01 26
PY2022 $517.89 25
PY2023 $1,474.67 21
PY2024 $880.69 32
PY2025 $676.63 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,038.55 259
PY2024 Principal investigator $408,860.46 382
PY2023 Principal investigator $228,849.11 170
PY2022 Recipient $321.00 1
PY2022 Principal investigator $248,165.36 66
PY2021 Recipient $2,700.00 2
PY2021 Principal investigator $244,500.15 37
PY2020 Recipient $643.47 2
PY2020 Principal investigator $251,307.20 46
PY2019 Recipient $4.75 1
PY2019 Principal investigator $990,287.65 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,164.22 12/31/2022 Non-covered Recipient Entity
NW ARKANSAS CLINICAL TRIALS CENTER
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889828613
Principal investigator 1 Bausch Health US, LLC $1,000.00 12/02/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342739
Principal investigator 1 ABBVIE INC. $1,172.40 11/16/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889821119
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $6,976.12 11/11/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710143
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $24,565.50 11/11/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710163
Principal investigator 1 ABBVIE INC. $506.40 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889820249
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,278.75 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710093
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,305.00 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710103
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $503.62 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710113
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,305.00 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710359
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,278.75 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710369
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,305.00 11/09/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710379
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,921.64 11/04/2022 Non-covered Recipient Entity
Suny Research Foundation State Of Buffalo Ny
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 933188549
Principal investigator 1 Eli Lilly and Company $1,000.00 10/20/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917828689
Principal investigator 1 ABBVIE INC. $253.20 10/12/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889815215
Principal investigator 1 Bausch Health US, LLC $850.00 10/07/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342741
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $10,974.37 09/21/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709981
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $875.62 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709891
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $2,095.00 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709901
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709911
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,287.50 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709921
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,566.25 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709931
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,147.50 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709941
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,937.50 09/19/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709951
Principal investigator 1 Bausch Health US, LLC $725.00 08/26/2022 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342743
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $2,325.37 08/26/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709971
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,278.75 08/24/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709835
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,305.00 08/24/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709845
Principal investigator 1 ABBVIE INC. $1,400.40 08/16/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889806395
Principal investigator 1 Bausch Health US, LLC $1,350.00 08/12/2022 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342745
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $10,818.00 07/26/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709961
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709819
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,836.62 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709825
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,330.00 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709855
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,287.50 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709865
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $364.25 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709873
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,278.75 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709881
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710455
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710465
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710475
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 07/25/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936710485
Principal investigator 1 ABBVIE INC. $6,500.00 07/20/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889801645
Principal investigator 1 ABBVIE INC. $3,066.00 07/14/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889800603
Principal investigator 1 Bausch Health US, LLC $2,190.00 06/24/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342733
Principal investigator 1 Bausch Health US, LLC $2,190.00 06/24/2022 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342747
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $898.87 06/24/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709693
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,997.00 06/24/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709809
Principal investigator 1 ABBVIE INC. $1,172.40 06/16/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889795963
Principal investigator 1 Journey Medical Corporation $5,000.00 06/08/2022 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, PLLC
DFD-29-CD-004 No dispute reported 06/30/2026 923102423
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $892.50 06/01/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709713
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $28.00 06/01/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709719
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,150.87 06/01/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709729
Principal investigator 1 Bausch Health US, LLC $725.00 05/26/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342737
Principal investigator 1 ABBVIE INC. $3,334.20 05/12/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement No dispute reported 06/30/2026 889791701
Principal investigator 1 ABBVIE INC. $1,533.00 05/11/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889790927
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,041.96 05/03/2022 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center, Llc
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 933188499
Principal investigator 1 Bausch Health US, LLC $7,415.00 04/15/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342735
Recipient Eli Lilly and Company $321.00 04/01/2022 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 917806359
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $803.25 03/16/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709683
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $7,639.87 02/23/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) No dispute reported 06/30/2026 936709663
Principal investigator 1 ABBVIE INC. $1,380.60 02/22/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889778181
Principal investigator 1 Bausch Health US, LLC $10,490.00 02/11/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE CONTROLLED, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF IDP-126 GEL TO EPIDUO? FORTE GEL (0.3% ADAPALENE/2.5% BPO), IN THE TREATMENT OF ACNE VULGARIS No dispute reported 06/30/2026 960342731
Principal investigator 1 Incyte Corporation $10,542.60 01/28/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo No dispute reported 06/30/2026 905225733
Principal investigator 1 Novartis Pharmaceuticals Corporation $147.00 01/15/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CENTER
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 909410177
Principal investigator 1 Eli Lilly and Company $57,722.00 01/12/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 917833703
Principal investigator 1 Eli Lilly and Company $128.00 01/05/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 917828683
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,253.26 01/04/2022 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER PLLC
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 909410187